Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.58

+0.9%

Dec 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (23734)	5/23/2007 8:58:47 PM
From: georgiabiotech	Read Replies (1) of 52153

Avandia trial analysis IJ I reviewed your post on MI's between the avandia group 86 MI's .60% and 72 MI,s .62% in the control group so I also was not impressed with the data but then I went back and looked at the article and for Cardiovascular death there were 39 deaths .27% in the avandia group and 22 deaths .189% in the control group. I am not really dissagreeing with you on the MI data difference but there appears to be a difference in the cardiovascular death data between avandia and the control group. Bob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next